國際娛樂城

Novo Nordisk鈥檚 two-year suspension from the 國際娛樂城 (國際娛樂城) for serious breaches of the 國際娛樂城 Code of Practice has come to an end [1].

Novo Nordisk鈥檚 return to full membership of the 國際娛樂城 follows extensive audits of Novo Nordisk鈥檚 compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA). Specifics of the original case are available on the [2].

Novo Nordisk, supported by the independent PMCPA audit reports, has demonstrated to the 國際娛樂城 Board鈥檚 satisfaction that the company has made clear, significant, and sustained improvements to ensure it is able to properly adhere to the strict industry standards in the 國際娛樂城 Code of Practice.

Richard Torbett, Chief Executive of the 國際娛樂城, said: 鈥淭he UK rightly has some of the highest standards in the world for how pharmaceutical companies can behave and operate 鈥� embodied by the 國際娛樂城 Code of Practice. In 2021, Novo Nordisk fell short of these standards, and it is right that their peers held them accountable.

鈥淥ver the past two years, Novo Nordisk has responded positively and actively to the requirements laid down by the 國際娛樂城 Board, and I am pleased to welcome them back into full engagement as 國際娛樂城 members.鈥�

Sebnem Avsar Tuna, General Manager of Novo Nordisk UK said: 鈥淲e welcome the decision today to have our membership to the 國際娛樂城 restored. Throughout the audit process we have considerably strengthened our compliance processes and we firmly believe that we now have the right foundations and governance in place to be fully and effectively self-regulating.

鈥淔rom day one, we have taken the decision to suspend our membership extremely seriously, and we have greatly valued the cooperation from the 國際娛樂城 and the PMCPA during what has been a very robust and thorough review process.

鈥淣ovo Nordisk has had a significant presence in the UK for more than fifty years and we remain committed to our purpose of driving change to defeat serious chronic diseases and look forward to participating as a full member of the 國際娛樂城鈥�